2. Search Result
Search Result
Results for "

germinal center

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Peptides

2

Recombinant Proteins

2

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P5766
    AChRα(97-116)

    		nAChR
    AChRα(97-116) is a synthetic peptide corresponding to the 97-116 region of the rat acetylcholine receptor α-subunit, and also an inducer of autoimmune diseases. AChRα(97-116) can be used in studies related to experimental autoimmune myasthenia gravis .
    AChRα(97-116)
  • HY-10943
    GNF-7
    2 Publications Verification

    		 Bcr-Abl Ack1 Cancer
    GNF-7 is a multikinase inhibitor. GNF-7 is a Bcr-Abl inhibitor, with IC50s of 133 nM and 61 nM for Bcr-Abl WT and Bcr-Abl T315I, respectively. GNF-7 also possesses inhibitory activity against both ACK1 (activated CDC42 kinase 1) and GCK (germinal center kinase) with IC50s of 25 nM and 8 nM, respectively. GNF-7 can be used for the research of hematologic malignancies .
    GNF-7
  • HY-12291
    HG6-64-1

    HMSL 10017-101-1

    		 Raf Apoptosis Cancer
    HG6-64-1 (HMSL 10017-101-1) is a B-raf kinase modulator.HG6-64-1 modulates B-raf kinase activity, including the V600E mutant form and the drug-resistant gatekeeper mutation T529I. HG6-64-1 is a germinal center kinase inhibitor. HG6-64-1 induces cell cycle arrest and apoptosis. HG6-64-1 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .
    HG6-64-1
  • HY-148631
    GSK137

    		BCL6 Inflammation/Immunology Cancer
    GSK137 is an orally active, potent and selective B-cell lymphoma 6 (BCL6) inhibitor. GSK137 blocks the interaction between BCL6 and corepressors (e.g., SMRT), reducing the number of germinal center B cells. GSK137 is promising for research of autoimmune diseases such as systemic lupus erythematosus (SLE) and B-cell-related tumors such as diffuse large B-cell lymphoma .
    GSK137
  • HY-179075
    PROTAC BCL6/IKZF1/3 Degrader-1

    		PROTACs BCL6 IKZF Family Cancer
    PROTAC BCL6/IKZF1/3 Degrader-1 is a selective and orally active BCL6 and IKZF1/3 PROTAC degrader. PROTAC BCL6/IKZF1/3 Degrader-1 exhibits superior antiproliferative effects in various germinal center B-cell-like (GCB) and activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) cell lines. PROTAC BCL6/IKZF1/3 Degrader-1 can be used for the research of cancer, such as lymphoma . (Structure Note: Pink: BCL6/IKZF1/3 ligand (HY-179064); Blue: CRBN ligand (HY-41547); Black: linker (HY-42427); CRBN ligand-Linker: (HY-179066))
    PROTAC BCL6/IKZF1/3 Degrader-1
  • HY-143868
    HPK1-IN-27

    		MAP4K Cancer
    HPK1-IN-27 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-27 has the potential for the research of cancer diseases (extracted from patent WO2019016071A1, compound 38) .
    HPK1-IN-27
  • HY-143871
    HPK1-IN-30

    		MAP4K Cancer
    HPK1-IN-30 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-30 has the potential for the research of cancer diseases (extracted from patent WO2021175271A1, compound 3) .
    HPK1-IN-30
  • HY-174738
    Human CD40 mRNA

    		mRNA Inflammation/Immunology
    Human CD40 mRNA encodes the human CD40 molecule (CD40) protein, a member of the TNF-receptor superfamily. CD40 is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation.
    Human CD40 mRNA
  • HY-162754
    LMP7/LMP2-IN-1

    		Proteasome Inflammation/Immunology
    LMP7/LMP2-IN-1 (Compound 19) is the orally active inhibitor for immunoproteasome subunits LMP7 and LMP2 with IC50 of 257 and 10 nM. LMP7/LMP2-IN-1 reduces the generation of antibody, downregulates the cells in spleen germinal center B and in plasma in NP-OVA-immunized mice, and can be used in research about autoimmune diseases .
    LMP7/LMP2-IN-1
  • HY-162268
    MALT1-IN-13

    		MALT1 Apoptosis Inflammation/Immunology Cancer
    MALT1-IN-13 (compound 10m) is inhibitor for mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), which to binds MALT1 protease covalently and irreversibly, inhibits MALT1 with the IC50 of 1.7 μM. MALT1-IN-13 inhibits proliferation against ABC-DLBCL and induces apoptosis in ABC-DLBCL HBL1. MALT1-IN-13 regulates mTOR and PI3K-Akt pathways .
    MALT1-IN-13
  • HY-151395
    Tubulin polymerization-IN-34

    		Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-34 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, demonstrates high selectivity against marginal zone lymphoma VL51 cell line .
    Tubulin polymerization-IN-34
  • HY-151396
    Tubulin polymerization-IN-35

    		Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-35 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, demonstrates high selectivity against marginal zone lymphoma VL51 cell line .
    Tubulin polymerization-IN-35
  • HY-151394
    Tubulin polymerization-IN-33

    		Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-33 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, exhibits high antiproliferative activity against the NCI panel .
    Tubulin polymerization-IN-33
  • HY-148640
    WK500B

    		BCL6 MDM-2/p53 Histone Methyltransferase CXCR Apoptosis Cancer
    WK500B is a potent and orally active BCL6 inhibitor with a KD of 1.61 μM. WK500B engages intracellular BCL6 and disrupts BCL6‑corepressor interactions to reactivate BCL6 target genes. WK500B exerts cytotoxicity against diffuse large B‑cell lymphoma cells and induces apoptosis and cell cycle arrest. WK500B suppresses germinal center formation in C57BL/6 mice and DLBCL tumor growth in SCID xenograft models without observable toxicity. WK500B can be used for the study of diffuse large B‑cell lymphoma (DLBCL) .
    WK500B
  • HY-182706
    NSC 373981

    		G-quadruplex Bcl-2 Family c-Myc Ras Cancer
    NSC 373981 is a CARD11 G4 stabilizer. NSC 373981 stabilizes the CARD11 G4 structure and inhibits CARD11 transcription in cells. NSC 373981 also inhibits BCL2 and MYC. NSC 373981 suppresses the transcription of KRAS and TERT. NSC 373981 exhibits anticancer activity against diffuse large B-cell lymphoma .
    NSC 373981

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: